Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last --
Change Today 0.00 / 0.00%
Volume 0.0
8158 On Other Exchanges
Symbol
Exchange
8158 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

china regenerative medicine (8158) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA REGENERATIVE MEDICINE (8158)

Related News

No related news articles were found.

china regenerative medicine (8158) Related Businessweek News

No Related Businessweek News Found

china regenerative medicine (8158) Details

China Regenerative Medicine International Limited, an investment holding company, engages in the research and development of bio-medical and healthcare products, and medical techniques in the People's Republic of China. It operates through Tissue Engineering, Stem Cell, Cosmetic and Health Products, and Medical Products and Equipment segments. The company offers ActivSkin, a tissue-engineered skin product; Acellular Corneal Stroma for use in the treatment of ophthalmology; Calcined Bovine Bone, a protein-detracted natural bone regenerative product and a bone substitute material for inducing natural bone regeneration; and Acellular Small Intestinal Submucosa, which is applied to anal fistula disease. It is also involved in the research and development of Recombinant Human Acellular Dermal Matrix that is targeted and applied for second degree burns; Selective Acellular Skin for use as wound dressings; Acellular Amniotic Membrane, an anti-adhesion agent for muscle and tender rebuilding operations; and Absorbable Dental Membrane for jawbone defect restoration, which are in Stage II business development process. In addition, the company provides Cell Sheet-Autologous Chondrocyte Implantation, a medical technique for repairing knee and other relevant cartilage damages; and produces and sells cellular and stem cell therapy products. Further, it develops a series of cosmetic products and stem cell based anti-aging products; and offers contract research organization services of drug screening, drug efficacy, and toxicity assays in the pre-clinical drug development, as well as trades in medical products and equipment. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Wanchai, Hong Kong.

471 Employees
Last Reported Date: 12/14/15
Founded in 1995

china regenerative medicine (8158) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $1.2M
Executive Director
Total Annual Compensation: $1.4M
Compliance Officer and Executive Director
Total Annual Compensation: $1.4M
Compensation as of Fiscal Year 2015.

china regenerative medicine (8158) Key Developments

China Regenerative Medicine International Limited Announces Management Changes

The board of directors of China Regenerative Medicine International Limited announced that with effect from 11 January 2016: Ms. Chan Yim has resigned as the company secretary and the authorized representative of the Company under the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited and for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance; Mr. Cheng Chai Fu has been appointed as the company secretary of the Company; and Mr. Wong Sai Hung has been re-designated from a non-executive Director to an executive Director and has been appointed as the Authorized Representative. Following Ms. Chan's resignation as the company secretary of the Company, Mr. Cheng has been appointed as the company secretary of the Company with effect from 11 January 2016. He is an associate member of The Hong Kong Institute of Chartered Secretaries with extensive experience in the areas of auditing, accounting and company secretarial work. Following Ms. Chan's resignation as the Authorized Representative, Mr. Wong has been re-designated from a non-executive Director to an executive Director and has been appointed as the authorized Representative with effect from 11 January 2016. Mr. Wong was a non-executive Director immediately prior to the re-designation and is the chairman of the Board. Mr. Wong joined the Group in June 2008 as a non-executive Director. Between August 2012 and April 2013, he had been re-designated as executive Director, and between July 2009 and August 2012 and from May 2013 to July 2014 as the vice-chairman of the Board. Currently, Mr. Wong is an independent non-executive director of the Hong Kong Exchanges and Clearing Limited, Ping An Insurance (Group) Company of China Ltd. and JPMorgan Chinese Investment Trust plc; a non-executive director of Credit China Holdings Limited and a director of One Asset Management Limited.

China Regenerative Medicine International Limited Announces Consolidated Unaudited Cash Flow Results for the Six Months Ended October 31, 2015

China Regenerative Medicine International Limited announced consolidated unaudited cash flow results for the six months ended October 31, 2015. For the period, the company reported net cash used in operating activities of HKD 169,874,000 compared with HKD 71,167,000 for the same period a year ago.

China Regenerative Medicine International Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 31, 2015

China Regenerative Medicine International Limited announced unaudited consolidated earnings results for the second quarter and six months ended October 31, 2015. For the quarter, revenue was HKD 3,421,000 against HKD 730,000 a year ago. Loss before income tax was HKD 27,074,000 against HKD 42,862,000 a year ago. Loss for the period was HKD 25,357,000 against HKD 40,689,000 a year ago. Loss for the period attributable to owners of the company was HKD 23,203,000 against HKD 39,128,000 a year ago. Basic loss per share for the period attributable to owners of the company was 0.132 cents against 0.331 cents a year ago. For the six months, revenue was HKD 5,009,000 against HKD 1,521,000 a year ago. Loss before income tax was HKD 75,295,000 against HKD 82,088,000 a year ago. Loss for the period was HKD 71,786,000 against HKD 77,743,000 a year ago. Loss for the period attributable to owners of the company was HKD 67,806,000 against HKD 75,208, 000 a year ago. Basic loss per share for the period attributable to owners of the company was 0.398 cents against 0.637 cents a year ago. Net cash used in operating activities was HKD 169,874,000 against HKD 71,167,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8158:HK $0.30 HKD 0.00

8158 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8158.
View Industry Companies
 

Industry Analysis

8158

Industry Average

Valuation 8158 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 832.8x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 690.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA REGENERATIVE MEDICINE, please visit www.crmi.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.